Health Economics›Post-transplant lymphoproliferative disorder›Consolidation after upfront therapy

Consolidation after upfront therapy

Post-transplant lymphoproliferative disorder · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
R-CHOP Variant #23	—	R 59 865	21d	~44.4 mo	~55.7 mo	~65	~R 3 891 219 PFS proxy · indirect	15
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~20.3 mo	—	~4	~R 208 PFS proxy · indirect	20

2 of 2 regimens shown